萝莉社

Skip to main content
(904) 244-0411

Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY)

  • Status
    Accepting Candidates
  • Age
    40 Years - 80 Years
  • Sexes
    All
  • Healthy Volunteers
I'm interested
Share this study

Description

This study will investigate the efficacy and safety of Tezepelumab as add-on treatment to inhaled maintenance therapy in a COPD population with a history of exacerbations. This study will compare the safety and tolerability of Tezepelumab with placebo in participants with moderate to very severe COPD. On completion of all screening assessments and confirmation of eligibility, participants will be randomized in a ratio of 1:1:1 to receive Tezepelumab (420 mg Q4W or 210 mg Q4W) or placebo Q4W. Participants will receive Tezepelumab or matching placebo for a minimum of 52 weeks (with the last dose at Week 48) and a maximum of 76 weeks of treatment (with the last dose at Week 72).

Details

Protocol number D5241C00007

Eligibility

This study will include eligible participants aged 40 to 80 years old with: 

1. Physician-diagnosed COPD for at least 12 months before Visit 1

2. COPD assessment test (CAT) score of > 15 at Visit 1

3. EOS ≥ 150 cells/μL during the screening period

4. Current or former smokers

5. History of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months before Visit 1 of which at least 1 of the 2 moderate exacerbations must have required treatment with systemic corticosteroids.

Participants should be receiving regular inhaled maintenance therapy or dual therapy for at least 3 consecutive months prior to Visit 1.  

Participants should be encouraged to continue on the same regular COPD background therapy throughout the study.

Participants with other significant respiratory diseases, including asthma will be excluded.


Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.